WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |

Search International and National Patent Collections
World Intellectual Property Organization
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/055242    International Application No.:    PCT/US2007/083254
Publication Date: 08.05.2008 International Filing Date: 31.10.2007
C07K 16/18 (2006.01), C07K 16/40 (2006.01), G01N 33/53 (2006.01), G01N 33/555 (2006.01), G01N 33/573 (2006.01), G01N 33/577 (2006.01), G01N 33/66 (2006.01)
Applicants: THE JOHNS HOPKINS UNIVERSITY [US/US]; Johns Hopkins Technology Transfer, 100 North Charles Street, 5th Floor, Baltimore, MD 21201 (US) (For All Designated States Except US).
HART, Gerald, W. [US/US]; (US) (For US Only).
PARK, Kyoungsook [KR/US]; (US) (For US Only).
SAUDEK, Christopher, D. [US/US]; (US) (For US Only).
WANG, Zihao [CN/US]; (US) (For US Only)
Inventors: HART, Gerald, W.; (US).
PARK, Kyoungsook; (US).
SAUDEK, Christopher, D.; (US).
WANG, Zihao; (US)
Agent: HAILE, Lisa, A.; DLA Piper US LLP, 4365 Executive Drive, Suite 1100, San Diego, CA 92121-2133 (US)
Priority Data:
60/855,981 01.11.2006 US
Abstract: front page image
(EN)The present invention is based on the discovery that hexosamine, and in particular the dynamic O-GlcNAcylation of proteins (modification of proteins by the sugar N- acetylglucosamine) both causes insulin-resistance (a hallmark of type II diabetes) and is responsible for glucose toxicity in the disease. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having pre-diabetes or diabetes. Also provided are methods of characterizing hyperglycemia in a subject, methods of identifying a protein as being associated with hyperglycemia, and kits for detecting pre¬ diabetes or diabetes.
(FR)La présente invention repose sur une découverte: l'hexosamine et, plus particulièrement, la O-GlcNAcylation dynamique de protéines (modification de protéines par le sucre N-acétylglucosamine), induit une résistance à l'insuline (un signe du diabète de type 2) et est responsable de la toxicité du glucose dans la maladie. Ainsi, l'invention concerne des méthodes permettant de diagnostiquer un malade et de déterminer s'il souffre d'un prédiabète ou d'un diabète ou s'il risque de développer un prédiabète ou un diabète. L'invention concerne également des méthodes permettant de caractériser une hyperglycémie chez un sujet, des méthodes permettant d'identifier une protéine et de déterminer si elle est associée à une hyperglycémie, ainsi que des trousses permettant de détecter un prédiabète ou un diabète.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)